Comments
Dr Reddy’s Laboratories is expected to post gains in the fourth quarter ended March 31, 2024 from newly acquired portfolios, contribution from Revlimid and stable sales in the US.
The Hyderabad-based drug-maker, which is slated to announce fourth quarter and FY24 results on Tuesday, is likely to post around 35 percent spurt in net profit at around ₹1,290 crore against ₹959 crore in the corresponding period of previous year.
According to analysts, the company is likely to post 13 percent growth in revenue at around ₹7,136 crore.
Dr Reddy’s net profit increased manifold to ₹959 crore in the fourth quarter ended March 31, 2023.
At 9.19 a.m., the company’s stock was trading at ₹6,322.45, up by ₹29.00, or 0.46 per cent, on the NSE.
Comments
COMMENT NOW
